Oxytocin’s Role in Obesity Management - Report - MDSpire

Oxytocin’s Role in Obesity Management

Researchers review human data on oxytocin’s effects on appetite, satiety, and metabolic health

  • By

  • Jess Allerton

  • January 9, 2026

  • 3 min

Share

Clinical Report: Oxytocin’s Role in Obesity Management

Overview

Revise to clearly differentiate between short-term and long-term effects of oxytocin on weight loss.

Background

Obesity is a chronic condition linked to various health complications, necessitating effective management strategies. Oxytocin, traditionally known for its roles in social bonding and reproduction, is emerging as a potential neuromodulator influencing appetite and energy balance. Understanding its effects could provide new avenues for obesity treatment.

Data Highlights

No numerical data available.

Key Findings

Cross-reference each key finding with specific studies to ensure clinical accuracy.

Clinical Implications

Highlight the need for caution in clinical application due to the lack of long-term efficacy.

Conclusion

Reiterate the necessity for further research and specify which aspects of oxytocin's role in obesity management require investigation.

References

  1. Alsayegh A.A., Frontiers in Endocrinology, 2025 -- Oxytocin’s Role in Obesity Management
  2. Endocrine Reviews, 2023 -- The Oxytocin System and Implications for Oxytocin Deficiency in Hypothalamic-Pituitary Disease
  3. Obesity and Endocrinology, 2023 -- Obesity Recognized as a Chronic Endocrine Disorder
  4. The New Gastroenterologist, 2025 -- Strategies for Managing Weight in Gastroenterology Practice
  5. Intranasal Oxytocin for Obesity - PMC, 2023
  6. The New Gastroenterologist — The Advancements in Obesity Treatment Approaches
  7. Endocrine Practice 31 (2025) 1351—1394
  8. Intranasal Oxytocin for Obesity - PMC
  9. Frontiers | A comprehensive analysis of oxytocin: a potential brain-based treatment to regulate obesity

Original Source(s)

Oxytocin’s Role in Obesity Management

  • by Jess Allerton

  • January 9, 2026

Related Content

After the Prescription: The Clinical Support Gap in Telehealth-Based GLP-1 Care

FDA Expands Afrezza to Pediatric Diabetes

The decision was supported by the phase 3 INHALE-1 trial and additional long-term safety, efficacy, and exposure data.

Pasteurized Akkermansia muciniphila alleviates high-fat diet-induced bone loss via Nr4a1-dependent Treg differentiation